 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
1 News |  |
- | vesencumab (MNRP1685A) / Roche, Macugen (pegaptanib) / Bausch Health
Journal: A Comprehensive Analysis of NRP1 in Malignancies Provide Therapeutic Implication for Treating Cancer Patients Infected with SARS-CoV-2. (Pubmed Central) - Nov 8, 2023
Overall, NRP1 appears to play a critical role in regulating immunological properties and metabolism in many tumor types. Specific inhibitors of the NRP1 antigen (pegaptanib, EG00229, or MNRP1685A) combined with other anti-SARS-CoV-2 strategies may aid in treating patients with lung and genitourinary cancers following SARS-CoV-2 infection.
- | vesencumab (MNRP1685A) / Roche
Journal, BRCA Biomarker: Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation. (Pubmed Central) - Mar 17, 2022
Specific inhibitors of the NRP1 antigen (pegaptanib, EG00229, or MNRP1685A) combined with other anti-SARS-CoV-2 strategies may aid in treating patients with lung and genitourinary cancers following SARS-CoV-2 infection. These data implicate NRP1 in the aggressive phenotype of claudin-low breast cancer and offer a novel targeted therapeutic approach to this poor prognosis subtype.
- | vesencumab (MNRP1685A) / Roche, Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 29, 2012
P1, N=24, Completed, Sponsor: Genentech
These data implicate NRP1 in the aggressive phenotype of claudin-low breast cancer and offer a novel targeted therapeutic approach to this poor prognosis subtype. Active, not recruiting --> Completed